The Progression of Current Biomarkers for the Diagnosis of Alzheimer's Disease

Abstract

Alzheimer's disease (AD) is a common degenerative disease with no cure. Atrophy of brain tissue, accumulation of amyloid deposition, and neuronal tangles are its main features and the most commonly used biomarkers for diagnosing AD. According to them, cerebrospinal fluid (CSF) measurement and imaging techniques are currently the mainstream methods for AD diagnosis. However, the high price and the need for technology cannot meet people's willingness to screen on a large scale, so people are forced to look for new biomarkers in cheaper and readily available blood. This brief commentary divides into three sections (CSF, imaging and blood) to describe the biomarkers found in AD. Among these biomarkers, the current development direction (machine automation) and joint diagnosis research are briefly described for biomarkers incorporated into clinical standards. The present research status and limitations of biomarkers that have received significant attention are discussed. Finally, the article summarizes the current status of biomarkers in diagnosing AD and looks forward to the feasibility of biomarkers in blood in the future.